AOXING PHARMACEUTICAL CO INC (OTCMKTS:AOXG) Sellers Increased By 200% Their Shorts

May 16, 2018 - By Theresa Judd

AOXING PHARMACEUTICAL CO INC (OTCMKTS:AOXG) recorded an increase of 200% in shorted shares. FINRA published in May AOXG’s total 900 shorted shares. That’s 200% up from 300 shares.

The stock decreased 0.14% or $0.0001 during the last trading session, hitting $0.0564.Currently Aoxing Pharmaceutical Company, Inc. is after 0.00% change in last May 16, 2017. AOXG has also 2,000 shares volume. AOXG underperformed by 11.55% the S&P 500.

Aoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China.The firm is worth $4.30 million. The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain.Currently it has negative earnings. The Company’s products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: